156 reports of this reaction
3.2% of all TROSPIUM CHLORIDE reports
#2 most reported adverse reaction
FATIGUE is the #2 most commonly reported adverse reaction for TROSPIUM CHLORIDE, manufactured by Padagis US LLC. There are 156 FDA adverse event reports linking TROSPIUM CHLORIDE to FATIGUE. This represents approximately 3.2% of all 4,882 adverse event reports for this drug.
TROSPIUM CHLORIDE has an overall safety score of 72 out of 100. Patients taking TROSPIUM CHLORIDE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among TROSPIUM CHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for TROSPIUM CHLORIDE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 156 FDA reports for TROSPIUM CHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.2% of all adverse event reports for TROSPIUM CHLORIDE, making it one of the most commonly reported side effect.
If you experience fatigue while taking TROSPIUM CHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.